Free Newsletter
Moody's gives Takeda top-notch rating
Moody's Investory Services gave a thumbs up to Takeda Pharmaceuticals, with an "Aa1" issuer rating, saying the company's outlook is stable and it is likely to remain strong financially following the its acquisition of Millennium Pharmaceuticals for $7.4 billion. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





